Core-binding factor-β positive acute myeloid leukaemia cells induce T-cell responses

被引:6
作者
Banat, GA [1 ]
Ihlow, K [1 ]
Usluoglu, N [1 ]
Hoppmann, S [1 ]
Hoeck, M [1 ]
Pralle, H [1 ]
机构
[1] Univ Giessen, Med Ctr, Dept Hematol & Oncol, D-35385 Giessen, Germany
关键词
acute myeloid leukaemia inv(16); co-stimulatory molecules; antigen presenting cell; cytotoxicity; immunotherapy;
D O I
10.1046/j.1365-2141.2003.04684.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The addition of specific cytokines is a mandatory prerequisite for the generation and subsequent function of leukaemia-derived dendritic cells (DC) believed to induce specific T-cell responses. In this study, we report the ability of blasts derived from cytogenetically classified acute myeloid leukaemia (AML) cells with the inversion of chromosome 16 to stimulate allogeneic and autologous T cells without additional cytokines. They displayed a measurable immunogenic effect. Sixteen of 17 established, stable AML cell lines, growing primary tumour cells from patients with a variety of chromosomal abnormalities, altered their surface marker expression pattern in proliferating culture. They lost the progenitor markers CD33, CD13 and CD34 while significantly increasing expression of the co-stimulatory molecules CD80 and CD86. Four cell lines derived from inv(16) positive blasts mounted allogeneic as well as autologous T cell activation with concomitant expression of CD25 and CD69. Moreover, oligoclonal expanded T cells were able to lyse inv(16) AML blasts in a specific major histocompatibility complex class I-restricted and CD80-dependent manner. AML blasts with karyotypes other than inv(16) activated T cells, but without inducing a significant proliferation. We conclude from this study that AML blasts derived from inv(16) positive patients may be preferential targets for AML immunotherapy strategies.
引用
收藏
页码:819 / 829
页数:11
相关论文
共 35 条
[1]  
ASHMAN LK, 1987, CANCER IMMUNOL IMMUN, V25, P250
[2]  
Bloomfield CD, 1998, CANCER RES, V58, P4173
[3]   NEW PERSPECTIVES OF CD28-B7-MEDIATED T-CELL COSTIMULATION [J].
BLUESTONE, JA .
IMMUNITY, 1995, 2 (06) :555-559
[4]   CBFβ-SMMHC, expressed in M4eo acute myeloid leukemia, reduces p53 induction and slows apoptosis in hematopoietic cells exposed to DNA-damaging agents [J].
Britos-Bray, M ;
Ramirez, M ;
Cao, WS ;
Wang, XP ;
Liu, PP ;
Civin, CI ;
Friedman, AD .
BLOOD, 1998, 92 (11) :4344-4352
[5]   Acute myelogenous leukemia blasts as accessory cells during T lymphocyte activation: possible implications for future therapeutic strategies [J].
Bruserud, O .
LEUKEMIA, 1999, 13 (08) :1175-1187
[6]  
CABACORTIPASSER.C, 1993, BLOOD, V81, P1369
[7]   Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses [J].
Choudhury, A ;
Liang, JC ;
Thomas, EK ;
Flores-Romo, L ;
Xie, QS ;
Agusala, K ;
Sutaria, S ;
Sinha, I ;
Champlin, RE ;
Claxton, DF .
BLOOD, 1999, 93 (03) :780-786
[8]   Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein [J].
Clark, RE ;
Dodi, IA ;
Hill, SC ;
Lill, JR ;
Aubert, G ;
Macintyre, AR ;
Rojas, J ;
Bourdon, A ;
Bonner, PLR ;
Wang, LH ;
Christmas, SE ;
Travers, PJ ;
Creaser, CS ;
Rees, RC ;
Madrigal, JA .
BLOOD, 2001, 98 (10) :2887-2893
[9]   High-dose cytosine arabinoside in the treatment of acute myeloid leukaemia [J].
Cole, N ;
Gibson, BE .
BLOOD REVIEWS, 1997, 11 (01) :39-45
[10]  
Cortes JE, 1999, CANCER-AM CANCER SOC, V85, P1506, DOI 10.1002/(SICI)1097-0142(19990401)85:7<1506::AID-CNCR11>3.3.CO